BACKGROUND: Real-world low-risk transcatheter aortic valve replacement (TAVR) outcomes in the United States have not been assessed comprehensively versus pivotal trials, which is a key component of ...

Counterintuitively, use of cerebral embolic protection failed to reduce the incidence of stroke in the 72 hours following a transcatheter aortic valve replacement or implantation found a late-breaking ...

Patients with severe aortic stenosis had comparable rates of death or disabling stroke, but the lead investigator cautions ...

Medtronic, Abbott and Boston Scientific provided updates on their devices used in heart valve disease treatment at the event.

Researchers found that at five years, patients with severe aortic stenosis who were treated with either TAVR or surgery had comparable rates of all-cause mortality or disabling stroke.

The DapaTAVI trial assessed the benefits of dapagliflozin in patients discharged after TAVI with a history of heart failure plus 1 of the following comorbidities: LVEF ≤40%, diabetes, or renal ...

The benefits of early TAVR for patients with asymptomatic, severe aortic stenosis are consistent regardless of NT-proBNP or ...

Medtronic has reported late-breaking data from the randomised Evolut Low Risk Trial’s five-year outcomes of the Evolut transcatheter aortic valve replacement (TAVR) system in low-risk aortic stenosis ...

The following is a summary of "A new guiding strategy for treating the free margin of the leaflet in an aortic root ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had ...

JenaValve today announced new results from an expanded cohort receiving its Trilogy transcatheter heart valve (THV) system.